SVB Wealth LLC Makes New Investment in Hims & Hers Health, Inc. (NYSE:HIMS)

SVB Wealth LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the first quarter, Holdings Channel.com reports. The firm purchased 27,206 shares of the company’s stock, valued at approximately $421,000.

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. raised its position in Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after acquiring an additional 428,671 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Hims & Hers Health by 103.2% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock valued at $389,000 after purchasing an additional 22,170 shares in the last quarter. Custom Index Systems LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter valued at $132,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Hims & Hers Health by 5.6% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after purchasing an additional 1,561 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in Hims & Hers Health by 30.7% during the fourth quarter. Russell Investments Group Ltd. now owns 167,328 shares of the company’s stock worth $1,489,000 after buying an additional 39,337 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock traded up $0.27 during midday trading on Tuesday, hitting $21.98. 1,660,798 shares of the company were exchanged, compared to its average volume of 7,429,916. The firm has a 50 day simple moving average of $21.13 and a 200-day simple moving average of $15.42. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period in the prior year, the company posted ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $12.54, for a total transaction of $2,368,655.52. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Andrew Dudum sold 188,888 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $12.54, for a total transaction of $2,368,655.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Melissa Baird sold 11,750 shares of the company’s stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total transaction of $141,940.00. Following the transaction, the chief operating officer now owns 538,932 shares in the company, valued at approximately $6,510,298.56. The disclosure for this sale can be found here. Insiders sold 981,485 shares of company stock valued at $18,604,404 in the last ninety days. Insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of recent analyst reports. Citigroup downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating and raised their price objective for the company from $16.00 to $20.00 in a research note on Wednesday, May 22nd. Jefferies Financial Group upped their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, June 27th. Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a report on Thursday, July 18th. Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Finally, Bank of America raised their price target on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Seven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $19.07.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.